


Pepptide Chemistry and Drug Design



Edited by
Ben M. Dunn

WILEY

PEPTIDE CHEMISTRY AND DRUG DESIGN

Edited by

BEN M. DUNN



WILEY

Copyright © 2015 by John Wiley & Sons, Inc. All rights reserved

Published by John Wiley & Sons, Inc., Hoboken, New Jersey
Published simultaneously in Canada

No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, scanning, or otherwise, except as permitted under Section 107 or 108 of the 1976 United States Copyright Act, without either the prior written permission of the Publisher, or authorization through payment of the appropriate per-copy fee to the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, (978) 750-8400, fax (978) 750-4470, or on the web at www.copyright.com. Requests to the Publisher for permission should be addressed to the Permissions Department, John Wiley & Sons, Inc., 111 River Street, Hoboken, NJ 07030, (201) 748-6011, fax (201) 748-6008, or online at <http://www.wiley.com/go/permissions>.

Limit of Liability/Disclaimer of Warranty: While the publisher and author have used their best efforts in preparing this book, they make no representations or warranties with respect to the accuracy or completeness of the contents of this book and specifically disclaim any implied warranties of merchantability or fitness for a particular purpose. No warranty may be created or extended by sales representatives or written sales materials. The advice and strategies contained herein may not be suitable for your situation. You should consult with a professional where appropriate. Neither the publisher nor author shall be liable for any loss of profit or any other commercial damages, including but not limited to special, incidental, consequential, or other damages.

For general information on our other products and services or for technical support, please contact our Customer Care Department within the United States at (800) 762-2974, outside the United States at (317) 572-3993 or fax (317) 572-4002.

Wiley also publishes its books in a variety of electronic formats. Some content that appears in print may not be available in electronic formats. For more information about Wiley products, visit our web site at www.wiley.com.

Library of Congress Cataloging-in-Publication Data:

Peptide Chemistry and Drug Design / edited by Ben M. Dunn.

p. ; cm.

Includes bibliographical references and index.

Summary: "This book details many of the problems and successes of peptides as potential drugs"—

Provided by publisher.

ISBN 978-0-470-31761-7 (hardback)

I. Dunn, Ben M., editor.

[DNLM: 1. Peptides—chemistry. 2. Drug Design. 3. Pharmaceutical Preparations. QU 68]

RM301.25

615.1'9—dc23

2014040280

Cover image courtesy of David Craik and Quentin Kaas, University of Queensland

Typeset in 10/12pt TimesLTStd by Laserwords Private Limited, Chennai, India

Printed in the United States of America

10 9 8 7 6 5 4 3 2 1

1 2015

**PEPTIDE CHEMISTRY
AND DRUG DESIGN**

PREFACE

This book is result of many conversations with peptide scientists at a variety of meetings, including American Peptide Society Symposia, meetings of the European Peptide Society, the Japanese Peptide Society, and the Australian Peptide Society. Some of these conversations were with the authors of the chapters in this book. One additional influence was a meeting in Dubai, where I had an excellent dinner with Waleed Danho, then with Roche Nutley. Waleed had given an excellent talk about the value of peptide chemistry and peptides as elements in the drug-discovery process. Over a delicious dinner of baked fish and many other courses, we discussed the history of drug discovery and the role that peptides have played in the past. Waleed made the strong point that peptides still have great value in the discovery process and, with appropriate methods to deal with delivery and metabolism issues, can provide excellent drugs for the future.

At around this time, I was contacted by Jonathan Rose of John Wiley & Sons who asked if I would be interested in editing a book on peptides and drug discovery. Sometimes life provides a nice juxtaposition of ideas and I immediately accepted the invitation. Over the following years, I spoke with many scientists, emailed some more, and worked on putting together the chapters for this book. I want to thank Jonathan as well as Kari Capone of John Wiley for their patience and advice over the years it took to bring this together.

The book starts with a chapter provided by Nader Fatouhi, discussing the current state of peptides in drug discovery. I heard Nader speak at the 23rd American Peptide Symposium in the Kona region of the Big Island of Hawaii. As I felt that his presentation provided an update on the thoughts first revealed to me by Waleed Danho, I asked Nader to contribute the opening chapter of the book, as this sets the stage for what follows. In his chapter, Nader discusses the rising importance of peptides as

molecules for drug development as well as the issues facing scientists in this field, including cell penetration, stability, and targeting. Tools and techniques are available to address each of these limitations at this time.

Chapter 2 was contributed by Fernando Albericio and colleagues. This presents modern methods of peptide synthesis in a very readable format. Included are sections on solid supports for solid-phase peptide synthesis, which dominates most research level approaches, linkers, protecting groups, methods for peptide-bond formation, and a variety of methods to modify peptides to limit metabolism. In all cases the latest reagents and techniques are featured, thus making this chapter a great starting point for scientists starting out in the peptide field. The authors go on to discuss synthesis of peptides in solution, which still has great value in certain applications, including production of peptides in bulk. In addition, the combination of both solution- and solid-phase methods is discussed for cases where fragment condensation is used to prepare ever larger peptides. This discussion includes native chemical ligation, which permits selectively linking N-termini and C-termini of fragments, and which has several variations with more coming each year. The chapter concludes with a very valuable discussion of separation methods and methods for the analysis of the products of peptide synthesis. Again, this chapter is recommended as a great starting place for new scientists.

Anamika Singh and Carrie Haskell-Luevano have provided Chapter 3 that discusses the important topic of membrane receptors as targets for drug discovery. Due to the vital role of membrane receptors in cell signaling and control of metabolic events, a significant percentage of drugs in current use exert their function by interfering or stimulating binding and signaling events at membrane receptors, also known as G-protein coupled receptors (GPCRs). This chapter provides a catalog of systems where peptides are known to be involved and where it has been shown that synthetic peptides can modulate function. The Haskell-Luevano lab has provided outstanding research on the melanocortin receptors, but this chapter takes a broader approach and discusses a wide variety of these systems, including structural information as known and as modeled by other labs. Anyone involved in aspects of membrane signaling will find this chapter a highly valuable resource for methods, approaches, and strategies for attacking this important area of biology.

Gregg Fields and colleagues present Chapter 4 to introduce the use of peptides as inhibitors of enzymes. In the first part, the authors introduce enzymes and their classification and present several classical examples of the use of peptides to come up with compounds that provide the desired change in enzyme function to overcome a metabolic defect. In a second section, the area of HIV-1 infection and progression to AIDS is described, with emphasis on the value of peptides as modulators of growth and infection. As the human immunodeficiency virus goes through a complicated life cycle, the authors point out that there are multiple targets for approaching therapy and a combination strategy, known as HAART (highly active antiretroviral therapy) has provided the optimal approach to treatment of affected individuals. The Fields lab has made major contributions to discoveries in the area of matrix metalloproteinases and this chapter presents a thorough discussion of this system. The enzymes in this family provide a great example of the development of inhibitors through a process of

discovery of aspects of structure and function that can guide the process. The chapter continues with nice discussions of several other systems where peptide chemistry has been key in new discoveries that have driven the drug-development process.

Jeffrey-Tri Nguyen and Yoshiaki Kiso have provided Chapter 5, which continues the discussion of enzyme inhibitors from the aspect of peptides. The highly productive Kiso lab has led the way in creating a very large catalog of peptide derivatives for use in drug discovery in several systems. They begin this chapter by discussing the advantages and disadvantages of peptides as potential drugs and come down on the side of the beneficial role that peptides play. In particular, they make the important point that the use of peptides can frequently define the pharmacophore, or structural model, which can then be transformed into a small molecule of non-peptide nature for further development as a potential drug. This chapter further focuses on the process of the design of potential inhibitors and reviews the history of discovery from natural sources as well as through *ab initio* design. They discuss the advantages of learning from the natural substrates of an enzyme and introduce the important concept of the transition state analog; the critical role that structural information on the target protein can provide. This chapter provides an excellent discussion of systems where targeting with peptide molecules may provide opportunities for further drug discovery.

Sónia T. Henriques and David J. Craik describe many peptide inhibitors from natural sources in Chapter 6. The introduction to their chapter discusses the value of finding compounds from nature and describes a number of sources, including the antimicrobial peptides from many bacteria. In both bacterial and plant worlds, there is a continual war between competing systems, and this has led to the development through evolution of many natural peptides that serve as defensive molecules. The authors discuss the cyclotides, peptides that are connected end to end and that have multiple disulfide bonds. This arrangement is very stable and the molecules are found in venoms of several species as well as in plants. After this introduction, the authors turn to a discussion of the drug discovery process from their perspective. The chapter continues with an in depth discussion of a variety of systems where many methods are used to modify molecules isolated from nature and where the activity against many targets is tested. The wide diversity of structures and targets is featured in this chapter and the many discoveries have pushed research and drug discovery forward significantly.

Isuru R. Kumarasinghe and Victor J. Hruby have taken on the task of describing methods to limit the metabolism of peptide molecules in humans. This leads to a very detailed discussion of the chemistry of peptide modification. As Victor Hruby is the world leader in this aspect of peptides, the chapter is thoroughly exciting and interesting. A main concern is the digestion of peptides by proteolytic enzymes present in both the digestive tract and the circulation. The first step is to define the pharmacophore residues of a naturally occurring and effective peptide. This will show the absolutely critical functional groups and their stereochemical relationships that must be maintained. Then replacement of some nonessential amino acids by non-natural amino acids, with the D-amino acid isomer, or with peptide-bond isosteres may be sufficient to block degradation by proteases. In addition, cyclization can sometimes provide more stability and also enhance passage of peptides through

the blood–brain-barrier. Other strategies include replacement of specific the amino acids with the *N*-methyl derivatives, with topographically constrained derivatives, or with the halogenated derivatives of aromatic amino acids. Finally, the use of the “multiple-antigenic-peptide” approach where many molecules are attached to a carrier with multiple attachment points can produce molecules that, due to their size, are not recognized by proteases. This chapter emphasizes the role of creative synthetic chemistry is the modification of peptides to achieve stability and bioavailability.

The book concludes with Chapter 8, provided by Jeffrey-Tri Nguyen Yoshiaki Kiso, that discusses the important area of peptide delivery. While progress in the past 50 years has permitted peptide chemists to make almost any sequence of amino acids that is desired in high yield and purity, getting those molecules into humans and into the specific area in the body where they can exert a therapeutic effect is a problem that has not progressed as rapidly. Thus, this chapter is very important for future advances in drug discovery based on peptides. Many of the readers may already be familiar with the Lipinski’s Rule of Five that includes recommendations for the size of a molecule, the number of hydrogen bonding atoms, and the lipophilicity. These rules are discussed in this chapter, but much more information is provided regarding solubility, membrane transport, and metabolic stability.

In conclusion, this book provides a primer for anyone in the field of drug discovery and specifically in the area of the use of peptides as molecules for both the discovery phase and, in favorable cases, the final phase of the creation of new molecular entities that can be moved into further studies to evaluate their potential as therapeutic drugs. I want to thank the authors of the chapters for their friendship, for many discussions, and for their excellent writing for this book.

Ben M. Dunn, Ph.D.
September 3, 2014

LIST OF CONTRIBUTORS

Fernando Albericio, Institute for Research in Biomedicine, Barcelona, Spain; CIBER-BBN, Networking Centre on Bioengineering, Biomaterials and Nanomedicine, Barcelona Science Park, Barcelona, Spain; Department of Organic Chemistry, University of Barcelona, Barcelona, Spain; School of Chemistry, University of KwaZulu-Natal, Durban, South Africa; School of Chemistry, Yachay Tech, Yachay City of Knowledge, Urcuqui, Ecuador

Sabrina Amar, Departments of Chemistry and Biology, Port St. Lucie, FL USA

David J. Craik, Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland, Australia

Ayman El-Faham, Department of Chemistry, Alexandria University, Alexandria, Egypt; Department of Chemistry, King Saud University, Riyadh, Kingdom of Saudi Arabia

Gregg B. Fields, Departments of Chemistry and Biology, Port St. Lucie, FL USA; Departments of Biochemistry, University of Texas Health Science Center, San Antonio TX, USA

Nader Fotouhi, Global Alliance for TB Drug Development, Research and Development, New York, NY, USA

Athanassios S. Galanis, Department of Pharmacy, University of Patras, Patras, Greece

Carrie Haskell-Luevano, Department of Medicinal Chemistry, University of Minnesota, Minneapolis, MN, USA

Sónia T. Henriques, Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland, Australia

- Victor J. Hruby**, Department of Chemistry and Biochemistry, The University of Arizona, Tucson, AZ, USA
- Yoshiaki Kiso**, Department of Molecular Pharmacy, Kobe Gakuin University, Kobe, Japan
- Anna Knapinska**, Departments of Chemistry and Biology, Port St. Lucie, FL USA
- Isuru R. Kumarasinghe**, Department of Chemistry and Biochemistry, The University of Arizona, Tucson, AZ, USA
- Jeffrey-Tri Nguyen**, Department of Medicinal Chemistry, Kyoto Pharmaceutical University, Kyoto, Japan
- Eliandre de Oliveira**, Proteomics Platform Barcelona Science Park, Barcelona, Spain
- Trista K. Robichaud**, Departments of Periodontics, University of Texas Health Science Center, San Antonio TX, USA; Departments of Biochemistry, University of Texas Health Science Center, San Antonio TX, USA
- Anamika Singh**, Department of Medicinal Chemistry, University of Minnesota, Minneapolis, MN, USA
- Judit Tulla-Puche**, Institute for Research in Biomedicine, Barcelona, Spain; CIBER-BBN, Networking Centre on Bioengineering, Biomaterials and Nanomedicine, Barcelona Science Park, Barcelona, Spain
- Aikaterini A. Zompra**, Department of Pharmacy, University of Patras, Patras, Greece

CONTENTS

Preface	xi
List of Contributors	xv
1 Peptide Therapeutics	1
<i>Nader Fotouhi</i>	
1.1 History of Peptides as Drugs,	1
1.2 Factors Limiting the Use of Peptides in the Clinic,	2
1.3 Advances that have Stimulated the Use of Peptides as Drugs,	3
1.4 Development of Peptide Libraries,	4
1.5 Modification of Peptides to Promote Stability and Cell Entry,	6
1.6 Targeting Peptides to Specific Cells,	7
1.7 Formulations to Improve Properties,	7
References,	8
2 Methods for the Peptide Synthesis and Analysis	11
<i>Judit Tulla-Puche, Ayman El-Faham, Athanassios S. Galanis, Eliandre de Oliveira, Aikaterini A. Zompra, and Fernando Albericio</i>	
2.1 Introduction,	11
2.2 Solid Supports,	13
2.3 Linkers,	15
2.4 Protecting Groups,	17
2.4.1 The Special Case of Cysteine,	18
2.5 Methods for Peptide Bond Formation,	20

- 2.5.1 Peptide-Bond Formation from Carbodiimide-Mediated Reactions, 20
- 2.5.2 Peptide-Bond Formation from Preformed Symmetric Anhydrides, 22
- 2.5.3 Peptide-Bond Formation from Acid Halides, 23
- 2.5.4 Peptide-Bond Formation from Phosphonium Salt-Mediated Reactions, 23
- 2.5.5 Peptide-Bond Formation from Aminium/Uronium Salt-Mediated Reactions, 24
- 2.6 Solid-Phase Stepwise Synthesis, 26
 - 2.6.1 Long Peptides, 27
- 2.7 Synthesis in Solution, 29
 - 2.7.1 N^α Protection of the N-Terminal Amino Acid Derivative or Fragment, 30
 - 2.7.2 Carboxy-Group Protection of the C-terminal Amino-Acid Derivative or Fragment, 31
 - 2.7.3 Peptide Bond Formation, 34
- 2.8 Hybrid Synthesis—Combination of Solid and Solution Synthesis, 34
 - 2.8.1 Classical Segment Condensation, 35
 - 2.8.2 Native Chemical Ligation, 36
- 2.9 Cyclic Peptides, 37
- 2.10 Depsipeptides, 38
- 2.11 Separation and Purification of Peptides, 40
 - 2.11.1 Gel-Filtration Chromatography, 41
 - 2.11.2 Ion-Exchange Chromatography, 41
 - 2.11.3 Reverse-Phase High Performance Liquid Chromatography, 42
- 2.12 Characterization of Peptides Through Mass Spectrometry, 43
 - 2.12.1 Ionization Source, 44
 - 2.12.2 Mass Analysers, 45
 - 2.12.3 Peptide Fragmentation, 49
 - 2.12.4 Quantification by MS, 51
- 2.13 Conclusions, 52
 - Acknowledgments, 53
 - Abbreviations, 53
 - References, 56

3 Peptide Design Strategies for G-Protein Coupled Receptors (GPCRs)

75

Anamika Singh and Carrie Haskell-Luevano

- 3.1 Introduction, 75
- 3.2 Classification of GPCRs, 76
- 3.3 Catalog of Peptide-Activated G-Protein Coupled Receptors, 77
- 3.4 Structure of GPCRs: Common Features, 77
 - 3.4.1 Crystal Structures, 77

- 3.5 GPCR Activation, 93
 - 3.5.1 Ligand (Peptide) Binding and Receptor Activation, 94
 - 3.5.2 Common Structural Changes among GPCRs, 95
 - 3.5.3 G-Protein Coupled Intracellular Signaling Pathways, 95
- 3.6 Structure and Function of Peptide Hormones, 98
- 3.7 Design Approaches for GPCR Selective Peptide Ligands, 98
 - 3.7.1 Structure–Activity Relationship (SAR) Studies, 99
 - 3.7.2 Chimeric Peptide Analogs, 103
 - 3.7.3 Combinatorial Libraries, 103
 - 3.7.4 Three-Dimensional (3D) GPCR Homology Molecular Modeling, 104
- 3.8 Conclusions, 105
 - Acknowledgments, 105
 - References, 106

- 4 Peptide-Based Inhibitors of Enzymes** **113**
Anna Knapinska, Sabrina Amar, Trista K. Robichaud, and Gregg B. Fields
 - 4.1 Introduction, 113
 - 4.2 Angiotensin-Converting Enzyme and Neprilysin/Neutral Endopeptidase, 114
 - 4.3 Peptide Inhibitors of the HIV-1 Viral Life Cycle, 117
 - 4.4 Matrix Metalloproteinases, 118
 - 4.5 Anthrax Lethal Factor Inhibition by Defensins, 125
 - 4.6 Kinases, 127
 - 4.7 Glycosyltransferases (Oligosaccharyltransferases), 131
 - 4.8 Telomerase Inhibitors, 134
 - 4.9 Tyrosinase, 138
 - 4.10 Peptidyl-Prolyl Isomerase, 140
 - 4.11 Histone Modifying Enzymes, 143
 - 4.11.1 Histone Deacetylase, 144
 - 4.11.2 Histone Methyl-Transferase, 145
 - 4.12 Putting it all Together: Peptide Inhibitor Applications in Skin Care, 146
 - 4.13 Strategies for the Discovery of Novel Peptide Inhibitors, 147
 - Acknowledgments, 148
 - References, 148

- 5 Discovery of Peptide Drugs as Enzyme Inhibitors and Activators** **157**
Jeffrey-Tri Nguyen and Yoshiaki Kiso
 - 5.1 Introduction, 157
 - 5.1.1 Peptide Residue Nomenclature, 158
 - 5.1.2 Common Methods of Drug Design, 159
 - 5.1.3 Phases of Drug Development, 163

- 5.2 Enzyme Types That Process Peptides, 164
 - 5.2.1 Enzymes as Chemicals in Consumer and Medical Products, 164
 - 5.2.2 Nonspecific Enzyme Inhibitors, 166
- 5.3 Amino Acid Drugs, 166
 - 5.3.1 Thyroid Hormones, 166
 - 5.3.2 An Ornithine Decarboxylase Inhibitor, 167
 - 5.3.3 Catecholamines, 168
- 5.4 Serine Proteases and Blood Clotting, 169
 - 5.4.1 Blood Coagulating Agents, 170
 - 5.4.2 Enzymes as Blood Anticoagulants, 171
 - 5.4.3 Direct Thrombin Inhibitors as Blood Anticoagulants, 171
- 5.5 Diabetes Mellitus, 174
 - 5.5.1 Peptide Hormones and Blood Glucose Regulation, 174
 - 5.5.2 Glucagon-Like Peptide-1 and Analogs, 175
 - 5.5.3 Dipeptidyl Peptidase-4 Inhibitors, 176
- 5.6 Renin–Angiotensin–Aldosterone System, 178
 - 5.6.1 ACE Inhibitors, 178
 - 5.6.2 Renin Inhibitors, 180
- 5.7 Penicillin and Cephalosporin Antibiotics, 183
- 5.8 HIV Protease, 184
 - 5.8.1 HIV-Specific Protease Inhibitors, 185
- 5.9 Peptide Drugs Under Development, 188
 - 5.9.1 Cathepsins, 188
 - 5.9.2 Cysteine Proteases, 189
 - 5.9.3 Secretases in Alzheimer’s Disease, 189
 - 5.9.4 Trypsin-Like Serine Proteases, 190
 - 5.9.5 Zinc Metalloproteases, 190
 - 5.9.6 Non-mammalian Proteases, 191
- 5.10 Discussion, 192
 - Acknowledgments, 193
 - References, 193

6 Discovery of Peptide Drugs from Natural Sources

203*Sónia T. Henriques and David J. Craik*

- 6.1 Introduction, 203
- 6.2 Peptides are Involved in the Host Defense Mechanism of Living Organisms, 206
 - 6.2.1 Cationic AMPs from Eukaryotes, Peptides that Target the Membrane, 207
 - 6.2.2 Peptides and the Host Defense in Bacteria – Bacteriocins, 211
 - 6.2.3 Cyclotides, Ultra-Stable Peptides that are Part of Plant Defense Mechanism, 216
- 6.3 Animal Venoms, a Rich Source of Peptides with Therapeutic Potential, 219

- 6.3.1 Conotoxins, a Naturally Occurring Combinatorial Peptide Library, 219
- 6.4 Optimization of Peptides for Drug Development, 224
 - 6.4.1 Chemical Modifications to Improve Activity, 224
- 6.5 Conclusions, 227
 - Acknowledgments, 227
 - References, 227

7 Modification of Peptides to Limit Metabolism 247

Isuru R. Kumarasinghe and Victor J. Hruby

- 7.1 Introduction, 247
- 7.2 Introduction of Unnatural Amino Acids, 248
- 7.3 Cyclization of Linear Peptides to Improve Stability Toward Blood and Brain Protease Degradation, 249
- 7.4 Introduction of D-Amino Acids into Peptides Improves Stability Toward Blood and Brain Protease Degradation, 253
- 7.5 Introduction of β -Amino Acids Increases the Stability Toward Blood and Brain Protease Degradation, 254
- 7.6 Introduction of Peptide Bond Isosteres, 255
- 7.7 Introduction of a N-Methylation of the Amide Bond of Peptides can Improve the Stability Toward Blood and Brain Protease Degradation, 258
- 7.8 Use of Unnatural Amino Acids – Use of Topographically Constrained Amino Acid, 260
- 7.9 Using Glycosylated Amino Acids to Increase the Resistance of the Proteolytic Degradation, 261
- 7.10 Creation of Peptides as Multiple Antigen Peptide (MAP) Dendrimeric Forms Increases the Stability Toward Blood and Brain Protease Degradation, 262
- 7.11 Halogenations of Aromatic Residues in Peptides can Reduce the Enzymatic Recognition Required for Peptide Hydrolysis, 263
- 7.12 Concluding Discussion, 264
 - References, 265

8 Delivery of Peptide Drugs 271

Jeffrey-Tri Nguyen and Yoshiaki Kiso

- 8.1 Introduction, 271
- 8.2 Lipinski's Rule of Five, 271
 - 8.2.1 Molecular Size, 272
 - 8.2.2 Lipophilicity, 274
 - 8.2.3 Chemical Stability, 278
 - 8.2.4 Routes of Administration, 282
- 8.3 Approaches to Delivering Peptide Drugs, 282
 - 8.3.1 Enzyme Inhibitors, 283

- 8.3.2 Permeation Enhancers, 284
- 8.3.3 Delivery of Peptide Drugs across the Blood–Brain Barrier, 286
- 8.4 Parenteral Peptide Drugs, 290
- 8.5 Topical Peptide Drugs for Local Effects, 294
 - 8.5.1 Cosmeceutical Peptides, 294
- 8.6 Intranasal Peptide Drug Delivery, 295
- 8.7 Enteral Peptide Drugs, 297
- 8.8 Different Routes of Administration for Insulin, 299
- 8.9 Discussion, 300
 - Acknowledgments, 301
 - References, 301

Index**311**